Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Neurology |
| Therapuetic Areas: | Neurology, Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 3/23/2019 |
| Start Date: | August 2010 |
| End Date: | December 2019 |
| Contact: | Jonathan Finlay, MD |
| Email: | Jonathan.Finlay@nationwidechildrens.org |
| Phone: | 614-722-4087 |
A Phase II Clinical Trial of Induction Chemotherapy Regimen Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx) Followed by a Single Cycle of High Dose Chemotherapy (HDC) and Autologous Hematopoietic Stem Cell Rescue (AuHSCR) for Patients With Recurrent or Progressive Intracranial Germ Cell Tumors
This study will look to see how well patients with relapsed or recurrent intracranial germ
cell tumors respond to the new combination of chemotherapy (in induction)of Gemcitabine,
Paclitaxel and Oxaliplatin (GemPOx) followed by consolidation chemotherapy and autologous
stem cell rescue.
cell tumors respond to the new combination of chemotherapy (in induction)of Gemcitabine,
Paclitaxel and Oxaliplatin (GemPOx) followed by consolidation chemotherapy and autologous
stem cell rescue.
Inclusion Criteria:
- ICGCT including pure germinoma and MMGCT.
- Patients with histologically proven germinoma and MMGCT, including endodermal sinus
tumor (yolk sac tumor), embryonal carcinoma, choriocarcinoma and mixed germ cell tumor
will be eligible for the study.
- Patients with mature/immature teratoma who have tumor marker elevations are eligible
on this study.
- Patient with ONLY mature and/or immature teratoma are ineligible in the absence of the
tumor marker elevations.
Exclusion Criteria:
- Patients with ICGCTs who are newly diagnosed are excluded from the study.
- Patients with the diagnosis of mature or immature teratoma in the absence of tumor
marker elevations are excluded from the study.
- Patients who are pregnant or breastfeeding are excluded from the study.
- Patients who have received previously a high dose chemotherapy regimen and autologous
transplant are excluded from this study.
- Patients who have received gemcitabine, oxaliplatin and/or paclitaxel are excluded
from this study.
We found this trial at
5
sites
550 1st Ave
New York, New York 10016
New York, New York 10016
(212) 263-7300
Phone: 212-263-8400
New York University Langone Medical Center NYU NYU Langone Medical Center, a world-class, patient-centered, integrated,...
Click here to add this to my saved trials
700 Childrens Drive
Columbus, Ohio 43205
Columbus, Ohio 43205
(616) 722-2000
Phone: 614-722-4087
Nationwide Children's Hospital At Nationwide Children’s, we are creating the future of pediatric health care....
Click here to add this to my saved trials
Childrens Hospital Los Angeles Children's Hospital Los Angeles is a 501(c)(3) nonprofit hospital for pediatric...
Click here to add this to my saved trials
Columbus, Ohio 43210
Phone: 614-293-4448
Click here to add this to my saved trials
1919 E Thomas Rd
Phoenix, Arizona 85006
Phoenix, Arizona 85006
(602) 933-1000
Phone: 602-933-0920
Phoenix Children's Hospital Phoenix Children's Hospital has provided hope, healing, and the best healthcare for...
Click here to add this to my saved trials